Cytokinetics, Incorporated - Product Pipeline Review - 2014

Published: Apr, 2014 | Pages: 53 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Cytokinetics, Incorporated - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Cytokinetics, Incorporated - Product Pipeline Review - 2014', provides an overview of the Cytokinetics, Incorporated's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Cytokinetics, Incorporated's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Cytokinetics, Incorporated including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Cytokinetics, Incorporated's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Cytokinetics, Incorporated's pipeline products

Reasons to buy

- Evaluate Cytokinetics, Incorporated's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Cytokinetics, Incorporated in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Cytokinetics, Incorporated's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Cytokinetics, Incorporated and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Cytokinetics, Incorporated
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Cytokinetics, Incorporated and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Cytokinetics, Incorporated Snapshot 5
Cytokinetics, Incorporated Overview 5
Key Information 5
Key Facts 5
Cytokinetics, Incorporated - Research and Development Overview 6
Key Therapeutic Areas 6
Cytokinetics, Incorporated - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Out-Licensed Products 11
Out-Licensed Products/Combination Treatment Modalities 12
Cytokinetics, Incorporated - Pipeline Products Glance 13
Cytokinetics, Incorporated - Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
Cytokinetics, Incorporated - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
Cytokinetics, Incorporated - Drug Profiles 16
tirasemtiv 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
CK-2127107 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
CK-2018488 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
CK-2018571 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
CK-2019165 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
CK-2066260 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Small Molecule To Inhibit Myosin For COPD, Asthma And Pulmonary Arterial Hypertension 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Small Molecules To Activate Myosin Light Chain Kinase For Cardiovascular Diseases 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Cytokinetics, Incorporated - Pipeline Analysis 27
Cytokinetics, Incorporated - Pipeline Products by Target 27
Cytokinetics, Incorporated - Pipeline Products by Route of Administration 28
Cytokinetics, Incorporated - Pipeline Products by Molecule Type 29
Cytokinetics, Incorporated - Pipeline Products by Mechanism of Action 30
Cytokinetics, Incorporated - Recent Pipeline Updates 31
Cytokinetics, Incorporated - Dormant Projects 39
Cytokinetics, Incorporated - Company Statement 40
Cytokinetics, Incorporated - Locations And Subsidiaries 51
Head Office 51
Appendix 52
Methodology 52
Coverage 52
Secondary Research 52
Primary Research 52
Expert Panel Validation 52
Contact Us 53
Disclaimer 53

List of Tables
Cytokinetics, Incorporated, Key Information 5
Cytokinetics, Incorporated, Key Facts 5
Cytokinetics, Incorporated - Pipeline by Indication, 2014 7
Cytokinetics, Incorporated - Pipeline by Stage of Development, 2014 9
Cytokinetics, Incorporated - Monotherapy Products in Pipeline, 2014 10
Cytokinetics, Incorporated - Out-Licensed Products in Pipeline, 2014 11
Cytokinetics, Incorporated - Out-Licensed Products/ Combination Treatment Modalities, 2014 12
Cytokinetics, Incorporated - Phase II, 2014 13
Cytokinetics, Incorporated - Phase I, 2014 14
Cytokinetics, Incorporated - Preclinical, 2014 15
Cytokinetics, Incorporated - Pipeline by Target, 2014 27
Cytokinetics, Incorporated - Pipeline by Route of Administration, 2014 28
Cytokinetics, Incorporated - Pipeline by Molecule Type, 2014 29
Cytokinetics, Incorporated - Pipeline Products by Mechanism of Action, 2014 30
Cytokinetics, Incorporated - Recent Pipeline Updates, 2014 31
Cytokinetics, Incorporated - Dormant Developmental Projects,2014 39